Victoza (liraglutide) is a prescription drug used to help manage type 2 diabetes and reduce the risk of certain diabetes-related heart problems. Victoza is given as a daily injection under the skin.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Intensive management of diabetes pays fewer dividends as patients age and raises the chances of hypoglycemia. But many people ...

Novo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as a treatment for type 2 diabetes in children for almost two decades.

Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity ... now marketed as Ozempic, ...

The global antidiabetics market is on a strong growth trajectory, with sales projected to soar from USD 106.3 billion in 2024 to USD 298.2 billion by 2034. This substantial increase reflects a robust ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

insulin use, or molecular structure of GLP-1 agonist agent (semaglutide [Ozempic], liraglutide [Victoza], dulaglutide [Trulicity], or exenatide [Byetta, Bydureon]). There was, however, an inverse ...

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out of pocket, GoodRx said.